TY - JOUR
T1 - Secondary Treatment for Men with Localized Prostate Cancer
T2 - A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform
AU - Beyer, Katharina
AU - Straten, Vera
AU - Remmers, Sebastiaan
AU - MacLennan, Steven
AU - MacLennan, Sara
AU - Gandaglia, Giorgio
AU - Willemse, Peter-Paul M
AU - Herrera, Ronald
AU - Omar, Muhammad Imran
AU - Russell, Beth
AU - Huber, Johannes
AU - Kreuz, Markus
AU - Asiimwe, Alex
AU - Abbott, Tom
AU - Briganti, Alberto
AU - Van Hemelrijck, Mieke
AU - Roobol, Monique J
AU - The Prias Consortium, null
AU - The Erspc Rotterdam Study Group, null
AU - The Pioneer Consortium, null
N1 - Funding Information:
Funding: PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use thatmay be made of the information contained herein.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5/5
Y1 - 2022/5/5
N2 - INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).
AB - INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).
KW - active surveillance
KW - oncology
KW - patient decision-making
KW - prostate cancer
KW - treatment choice
KW - treatment selection
UR - http://www.scopus.com/inward/record.url?scp=85130202827&partnerID=8YFLogxK
U2 - 10.3390/jpm12050751
DO - 10.3390/jpm12050751
M3 - Article
C2 - 35629173
SN - 2075-4426
VL - 12
SP - 1
EP - 8
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 5
M1 - 751
ER -